GlobeNewswire by notified

To the shareholders of Cavotec SA: Notice of the Annual General Meeting

Share

To be held on Thursday, June 2, 2022, in Lugano, Switzerland at 10.00 CEST at Cavotec SA headquarters in Lugano, Switzerland (Via Giovan BattistaPioda 14, CH-6900 Lugano, Switzerland).

Important communication: no personal attendance and exercise of rights exclusively through the Independent Proxy

Due to the ongoing uncertainties regarding Covid-19 the Annual General Meeting will again take place without physical attendance. As a result, the Board of Directors based on art. 27 of the Ordinance 3 on Measures to Combat the Coronavirus decided that the shareholders of Cavotec SA may exercise their rights at the Annual General Meeting exclusively through the Independent Proxy.

For more information regarding the appointment of the Independent Proxy please refer to the "Participation" section below.

Agenda and Proposals of the Board of Directors

  1. Appointment of the Chairman of the day

The Board of Directors proposes to elect Patrik Tigerschiöld (Chairman of the Board of Directors) as Chairman of the day for the Annual General Meeting 

  1. Annual report, financial statements and consolidated financial statements for the year 2021, report of the Statutory Auditors

The Board of Directors proposes that the annual report, the financial statements and the consolidated financial statement for the year 2021 be approved.

Please refer to the “Documentation” section below.

  1. Appropriation of available earnings

The Board of Directors proposes the following appropriation:

CHF
Carried forward from previous years(44,142,720)
Net gain/loss for the financial year 2021(45,407,500)
Total earningsavailable(89,550,220)
Appropriation to general statutory reserves (retained earnings)-
Appropriation to other reserves-
Proposed balance to be carried forward(89,550,220)







  1. Grant of Discharge from Liability to the Board of Directors and Persons entrusted with the Management from Activities during Business Year 2021

The Board of Directors proposes that discharge be granted to all the members of the Board of Directors and the Persons entrusted with the Management for the business year 2021.

  1. Capital reduction through allocation to Share premium reserve

Due to the above-mentioned sale of the airport business, the financial statements for the business year 2021 show a loss of CHF 45'407'500, leading to a capital loss in the amount of CHF 19'725'459. As a restructuring measure the Board of Directors proposes: 

  1.  to reduce the current share capital of CHF 120'631'296.00 by CHF 54'661'056 to CHF 65'970'240 by way of reducing the nominal value of the registered shares from CHF 1.28 by CHF 0.58 to CHF 0.70 and to allocate the nominal value reduction amount to the share premium reserve, which is increased from CHF 19'018'227 to CHF 73'679'283; 
  1.  to confirm as a result of the report of the auditors, that the claims of the creditors are fully covered notwithstanding the capital reduction; 
  1.  to amend articles 4, 4ter para. 1, 4quater and 4quinquies of the Articles of Association according to the following wording as per the date of the entry of the capital reduction in the commercial register (the proposed amendments are underlined): 

Article 4 - Share Capital 
The share capital of the Company is CHF 65'970'240 and is divided into 94'243'200 fully paid registered shares. Each share has a par value of CHF 0.70.

Article 4ter para. 1 
The Board of Directors shall be authorized to increase the share capital in an amount not to exceed CHF 6'597'024 through the issuance of up to 9'424'320 fully paid registered shares with a par value of CHF 0.70 per share by not later than June 2, 2024.

Article 4quater – Contingent Share Capital
The share capital may be increased in an amount not to exceed CHF 659'701 through the issuance of up to 942'430 fully paid registered shares with a par value of CHF 0.70 per share by the issuance of new shares to employees of the Company and group companies. The pre-emptive rights and advance subscriptions rights of the shareholders of the Company shall thereby be excluded. The shares or rights to subscribe for shares shall be issued to employees pursuant to the Long Term Incentive Plan 2020-2022 approved by the Board of Directors. Shares or subscription rights may be issued to employees at 10% discount compared with the market price quoted on the stock exchange of that time.

Article 4quinquies – Contingent Share Capital
The share capital may be increased in an amount not to exceed CHF 659'701 through the issuance of up to 942'430 fully paid registered shares with a par value of CHF 0.70 per share by the issuance of new shares to employees of the Company and group companies. The pre-emptive rights and advance subscriptions rights of the shareholders of the Company shall thereby be excluded. The shares or rights to subscribe for shares shall be issued to employees pursuant to the Long Term Incentive Plan 2021-2023 approved by the Board of Directors. Shares or subscription rights may be issued to employees at 10% discount compared with the market price quoted on the stock exchange of that time.

  1. Creation of additional contingent share capital in connection with employee participation

The Board of Directors proposes to create additional contingent share capital in an amount not to exceed CHF 659'701 enabling the issuance of up to 942'430 additional shares with a nominal value of CHF 0.70 each in connection with employee participation (Long Term Incentive Plan 2022-2024) by inserting the new article 4sexies of the Articles of Association with the following wording:

Article 4sexies – Contingent Share Capital
The share capital may be increased in an amount not to exceed CHF 659'701 through the issuance of up to 942'430 fully paid registered shareswith a par value of CHF 0.70 per share by the issuance of new shares to employees of the Company and group companies. The pre-emptiverights and advance subscriptions rights of the shareholders of the Company shall thereby be excluded. The shares or rights to subscribe forshares shall be issued to employees pursuant to the Long Term Incentive Plan 2022-2024 approved by the Board of Directors. Shares or subscriptionrights may be issued to employees at a 10% discount compared with the market price quoted on the stock exchange at that time.

  1. Renewal of Authorized Share Capital

The Board of Directors proposes to extend the duration of the existing authorized share capital in the amount not to exceed CHF 6'597'024 through theissuance of up to 9'424'320 fully paid registered shares with a par value of CHF 0.70 currently valid until May 27, 2023, by another year to June 2,2024, by amending article 4ter of the Articles of Association with the following wording (the proposed amendments are underlined): 

Article 4ter - Authorized Share Capital

The Board of Directors shall be authorized to increase the share capital in an amount not to exceed CHF 6'597'024 through the issuance of up to9'424'320fully paid registered shares with a par value of CHF 0.70per share by not later than June 2, 2024. Increases in partial amounts shall be permitted.

The Board of Directors shall determine the date of issue of new shares, the issue price, the type of payment, the conditions for the exercise of pre-emptive rights, and the beginning date for dividend entitlement. In this regard, the Board of Directors may issue new shares by means of a firmunderwriting ("Festübernahme") through a banking institution, a syndicate or another third party with a subsequent offer of these shares to theshareholders. The Board of Directors may permit pre-emptive rights that have not been exercised to expire or it may place these rights and/orshares as to which pre-emptive rights have been granted but not exercised, at market conditions or use them for other purposes in the interestof the Company.

The Board of Directors is further authorized to restrict or deny the pre-emptive rights of shareholders and allocate such rights to third parties if theshares are to be used:


1.1 for the acquisition of an enterprise, parts of an enterprise, or participations, or for new investments, or, in case of a share placements,for the financing or refinancing of such transactions; or
2.1 for the purpose of broadening the shareholder constituency in connection with a listing of shares on domestic or foreign stockexchanges or for the purpose of the participation of strategic partners; or
3.1 for the issuance of shares to employees or directors of the Company or of the group companies pursuant to share based incentiveplans approved by the Board of Directors.

  1. Approval of Remuneration

According to Art. 16b of the Articles of Association, the general meeting of shareholders shall annually approve the maximum aggregateremuneration amount (covering fixed and variable remuneration) each of:

  •  the Board of Directors for the period lasting until the next ordinary general meeting of shareholders;
  •  the CEO for the next business year. 

   8.1   Approval of Remuneration for the Board of Directors

The Board of Directors proposes to approve the maximum aggregate amount of EUR 500'000 for the remuneration (covering fixed and variable pay, pension contribution, social charges, etc.) for the Board of Directors for the period lasting until the next ordinary general meeting of shareholders.

   8.2     Approval of Remuneration of the CEO

The Board of Directors proposes to approve the maximum aggregate amount of EUR 2'900'000 for the remuneration (covering fixed and variable pay, pension contribution, social charges, etc.) for the CEO for the business year 2023.

  1. Re-election of five Directors, nomination of the Chairman of the Board of Directors

Pursuant to Art. 13 of the Articles of Association the Directors are elected each year to hold office until the following annual general meeting. Directorsmay be re-elected.

Patrik Tigerschiöld, Niklas Edling, Annette Kumlien, Erik Lautmann and Keith Svendsen stand for re-election. Fabio Cannavale does not stand for re-election. 

The Board of Directors, based on the recommendation of the Nomination Committee, proposes that Patrik Tigerschiöld, Niklas Edling, AnnetteKumlien, Erik Lautmann and Keith Svendsen be re-elected as Directors for a further one-year term of office expiring at the annual general meeting tobe held in 2023.

The Board of Directors, based on the recommendation of the Nomination Committee, furthermore proposes to nominate Patrik Tigerschiöld as Chairman of the Board of Directors. 

  1. Nominations for the Remuneration Committee

Pursuant to Art. 13 of the Articles of Association the members of the Remuneration Committee are elected each year to hold office until thefollowing annual general meeting. Members of the Remuneration Committee may be re-elected.

Patrik Tigerschiöld and Erik Lautmann stand for re-election, while Keith Svendsen is proposed for election. Fabio Cannavale does not stand for re-election.

The Board of Directors, based on the recommendation of the Nomination Committee, proposes that Erik Lautmann and Patrik Tigerschiöld be re-elected as members of the Remuneration Committee for a further one-year term of office expiring at the annual general meeting to be held in 2023.

The Board of Directors, based on the recommendation of the Nomination Committee, proposes that Keith Svendsen be elected as members of the Remuneration Committee for a further one-year term of office expiring at the annual general meeting to be held in 2023

  1. Re-election of Independent Auditor

The Board of Directors, based on the recommendation of the Nomination Committee, proposes that PricewaterhouseCoopers SA, Lugano,Switzerland be re-elected as Cavotec’s independent auditor for business year 2022.

  1. Election of an Independent Proxy

Pursuant to Art. 9a of the Articles of Association the independent proxy is elected each year to hold office until the following annual general meeting.The independent proxy may be re-elected.

Mr. Franco Brusa, Attorney-at-law, does not stand for re-election due to retirement. 

The Board of Directors proposes to elect Edoardo Buzzi, Attorney-at-law, as new Cavotec’s independent proxy for a one-year term expiring at theannual general meeting to be held in 2023.

Documentation

As of April 28, 2022, the following documents have been made available for inspection by shareholders at our registered office at Via Giovan Battista Pioda 14, 6900 Lugano, Switzerland:

  •  2021 Annual Report (including audited consolidated financial statements for the business year ended December 31, 2021 and auditedstatutory accounts of Cavotec SA, as well as the audited Remuneration Report);
  •  Nomination Committee Statement
  •  Remuneration Committee Statement
  •  Corporate Governance Report

All material for the 2022 AGM is also available on the Company’s website ir.cavotec.com, and shareholders may request copies at no cost of these documents at the following e-mail address: agm@cavotec.com.

Language

The AGM, deviating from the Swedish Corporate Governance Code (the "Code"), will be held in English and information and material will be available in English only. This is in accordance with an exemption granted by the Swedish Financial Supervisory Authority.

Participation

As announced above the AGM will take place in Lugano, Switzerland, without the personal attendance of shareholders who can exercise their rights exclusively through the Independent Proxy. Therefore, no admission tickets will be sent. 
The Annual General Meeting will be chaired by Patrik Tigerschiöld, Chairman of the Board of Directors.


Only shareholders entered in the share register with the right to vote on May 26, 2022, will be entitled to appoint the Independent Proxy and give him voting instructions. Further instructions for holders of SIX SIS registered shares and Euroclear Sweden registered shares follow below.

You may appoint the following proxy to represent you:

  •  Mr. Franco Brusa, Attorney-at-Law, Via G.B. Pioda 5, Lugano, Switzerland, has been appointed as independent shareholders' representative pursuantto Art. 9a of the Articles of Association (Independent Proxy).

You may use the proxy form attached to your invitation or the Electronic Proxy as set out on: https://anmalan.vpc.se/Cavotec2022 to appoint and instruct the Independent Proxy. 

Please note that the proxy form is also available on the Company’s website ir.cavotec.com.

Electronic Proxy

On the website https://anmalan.vpc.se/Cavotec2022 shareholders have the possibility to appoint the independent proxy and to give him instructions electronically. Registered shareholders will receive their personal login data (the “Individual Login”) by regular mail. The proxy granted electronically (the “Electronic Proxy”) has the same validity as the physical Proxy Form. Please note that you cannot vote twice (electronically and by mail); the instructions (electronic or by mail) which have been given later prevail. Additional information on the Electronic Proxy is available on https://anmalan.vpc.se/Cavotec2022.

Instructions to participate for Holders of SIX SIS registered shares

The following information is to shareholders who hold their Cavotec shares through SIX SIS AG.
To exercise your voting right through the Independent Proxy, you must be registered in the share register of Cavotec SA (“Share Register”) and complete the Proxy Form in accordance with the instructions set out below.

  1.  Registration in the Share Register of Cavotec SA:

In order to be entitled to voting rights at the AGM, Shareholders who are not already registered in the Share Register must request to be registered as shareholders in the Share Register prior to May 26, 2022 (the “Record Date”) in accordance with the instructions set out below:

  •  Shareholders must instruct their custodian bank to register them as shareholders in the Share Register of Cavotec SA by sending a Proxy Form to Cavotec SA, c/o Computershare Schweiz AG, Share Register, Baslerstrasse 90, CH-4600 Olten.
  •  The registration in the Share Register may be requested at any time.
  •  The registration must be completed on the Record Date at the latest.

Shareholders who are already registered in the Share Register do not have to perform any additional steps and will be provided automatically with the Proxy Form as well as with the Individual Login. 
Please note that the registration process may take time. To ensure their registration in time for the AGM, shareholders are therefore kindly invited to issue instructions to their custodian bank as soon as possible.

  1.  Proxy Voting:

Shareholders, who are registered in the Share Register, will receive a Proxy Form as well as the Individual Login by regular mail directly from Cavotec SA. Shareholders will be able to appoint the Independent Proxy, Mr. Franco Brusa, Attorney-at-law, Via G.B. Pioda 5, Lugano, Switzerland by using physical Proxy Forms. Alternatively, shareholders will also be able to appoint the Independent Proxy electronically on https://anmalan.vpc.se/Cavotec2022.

  •  The Proxy Form will be sent out via regular mail on April 28, 2022.
  •  In order to vote by proxy, the Proxy Form must be returned to Mr. Franco Brusa c/o Euroclear Sweden AB, PO Box 191, SE-101 23 Stockholm, Sweden, well in advance and in any case before May 27, 2022. In order to vote by Electronic Proxy, the Electronic Proxy must be completed according to the instructions set out on https://anmalan.vpc.se/Cavotec2022 by May 30, 2022, at 2pm at the latest.

Instructions to participate for Holders of Euroclear Sweden registered shares

The following information is to shareholders who hold their Cavotec shares through Euroclear Sweden AB, which shares trade on the Nasdaq Stockholm Exchange (“Euroclear Registered Cavotec Shares”).
To exercise your voting right, you must register your voting rights in the register of shareholders kept by Euroclear Sweden AB (“Register of Shareholders”) and complete the Proxy Form or the Electronic Proxy in accordance with the instructions set out below.

  1.  Registration Process for Voting Rights:

Direct-registered holders:
Holders of Euroclear Registered Cavotec Shares who hold their Euroclear Registered Cavotec Shares on an account directly with Euroclear Sweden, a CSD-account (Sw: Vp-konto), will be automatically included in the Register of Shareholders and do not have to perform any registration regarding voting rights.

Nominee-registered holders:
To be registered and entitled to vote at the AGM, shareholders who hold Euroclear Registered Cavotec Shares via a nominee (“Nominee-registered Holders”) must act in accordance with the instructions set out below:

  •  Nominee-registered Holders must request the nominee to register their Euroclear Registered Cavotec Shares temporarily in their own name in the Register of Shareholders.
  •  The registration in the Register of Shareholders will start on May 5, 2022, 21 calendar days prior to the Record Date.
  •  The registration in the Register of Shareholders must be completed at end of business day at the Record Date at the latest.

Nominee-registered holders with Non-affiliated Nominees:
To be registered and entitled to vote at the AGM, Nominee-registered Holders who hold their Euroclear Registered Cavotec Shares on custody accounts with nominees that are not affiliated directly as nominees to Euroclear Sweden AB (“Non-affiliated Nominees”) must follow the instructions below:

  •  Nominee-registered Holders with Non-affiliated Nominees must request their custodian bank or their nominee to register their Euroclear Registered Cavotec Shares temporarily in their own name in the Register of Shareholders. To do so, you must instruct the institution where you have your account to forward the registration request to Euroclear Sweden AB through its own custodians and/or nominees.
  •  The registration in the Register of Shareholders will start on May 5, 2022, 21 calendar days prior to the Record Date.
  •  The registration in the Register of Shareholders must be completed at end of business day at the Record Date at the latest.

Please note that the registration process may take time in such circumstances. To ensure their registration, shareholders are therefore kindly invited to issue instructions to their Non-affiliated Nominees as soon as possible.

  1.  Proxy Voting:

Nominee-registered Holders and direct-registered holders:
Holders of Euroclear Registered Cavotec Shares, registered on either a CSD-account (Sw Vp-konto) or a custody account with a nominee directly affiliated to Euroclear Sweden AB will receive a Proxy Form as well as the Individual Login by regular mail directly from Euroclear Sweden AB.


Recipients will be able to appoint a proxy or register to attend the AGM by using physical Proxy Forms. Recipients will also be able to grant a proxy and issue instructions to the Independent Proxy electronically by using the Electronic Proxy.
In case Holders of Euroclear Registered Cavotec Shares intend to appoint the Independent Proxy, the Proxy Form must be filled out, signed, dated and returned to the addresses below well in advance and in any case before May 27, 2022. In order to vote by Electronic Proxy, the Electronic Proxy must be completed according to the instructions set out on https://anmalan.vpc.se/Cavotec2022 by May 30, 2022, at 2pm at the latest.

Nominee-registered Holders with Non-affiliated nominees:
In order to appoint the Independent Proxy, Nominee-registered Holders with Non-affiliated Nominees must:

  •  Download the Proxy Form from the web site www.cavotec.com. The form will be available from https://anmalan.vpc.se/Cavotec2022.
  •  Print and fill out the Proxy Form downloaded from www.cavotec.com and return it signed and to the address below well in advance and in any case before May 27, 2022.

Additional Instructions for Non-affiliated Nominees:
Non-affiliated Nominees are urged to forward the above information to their custody-account holders holding Euroclear Registered Cavotec Shares.

Other information

As of the date of this notice, the total number of shares in Cavotec amounted to 94'243'200. Cavotec holds a total number of 0 shares as treasury shares. The total number of votes in Cavotec amounts to 94'243'200, of which Cavotec holds 0 votes.

For information on how your personal data is processed, see the integrity policy that is available at
https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf

Frequently Asked Questions

Q1: I want to vote at the meeting of shareholders of Cavotec SA. Do I have to appoint a proxy or register to attend the Meeting?
A1: In consideration of the situation caused by the coronavirus, the personal attendance at the AGM 2022 is prohibited and shareholders can therefore exercise their rights exclusively through the Independent Proxy After having been registered (see below questions 3), you must appoint Mr. Franco Brusa, Attorney-at-law (the Independent Proxy), well in advance and in any case before May 27, 2022. Please note that you have to fill out the Proxy Form and send it to Mr. Franco Brusa, Attorney-at-law, c/o Euroclear Sweden AB, PO Box 191, SE-101 23 Stockholm, Sweden. Please note that you can also appoint Mr. Franco Brusa, Attorney-at-law electronically by using the Electronic Proxy according to the instructions set out on https://anmalan.vpc.se/Cavotec2022

Q2: May I directly register for voting rights with Cavotec SA or send the Proxy Form to Cavotec SA or to Mr. Franco Brusa?
A2: Unfortunately, neither Cavotec SA nor Mr. Franco Brusa are able to process Proxy Forms sent to them. Please contact Euroclear Sweden AB, telephone: +46 8 402 92 83 for more information. If you hold your shares through SIX SIS AG (see question 3 below) and need further assistance with questions related to registering your share in the share register of Cavotec SA, please contact your custodian bank or Computershare Schweiz AG, telephone: +41 62 205 7700.

The following questions 3-5 are only relevant, if you have not already registered your shares for the AGM.

Q3: What do I have to do if I do not know whether I hold my Cavotec shares through SIX SIS AG or Euroclear Sweden AB or to which category of shareholders (i.e. Nominee-registered Holders or direct-registered holders) I belong?
A3: Your custodian bank should be able to provide you with the required information. However, you may also contact Euroclear Sweden AB, e-mail: generalmeetingservice@euroclear.eu, telephone: +46 8 402 92 83 or Computershare Schweiz AG, e-mail: share.register@computershare.ch, telephone: +41 62 205 7700 for further information. To register your shares, please follow the instructions set out above for the corresponding category of shareholders.

Q4: Who should I contact if I do not receive the necessary information/documents in connection with the AGM?
A4: Please contact Euroclear Sweden AB (telephone: +46 8 402 92 83).

Q5: When does the registration process for voting rights for shareholders who hold Cavotec Shares held through Euroclear Sweden AB via a nominee take place?
A5: The registration in the Register of Shareholders starts on May 5, 2022, 21 calendar days prior to the Record Date, and ends at the end of the business day on May 26, 2022. 

For questions regarding participation in the AGM, please contact:
Cavotec SA
c/o Euroclear Sweden AB Box 191
SE-10123 Stockholm, Sweden 
Telephone: +46 84029283

Lugano, April 27

For the Board of Directors of
Cavotec SA

Patrik Tigerschiöld Chairman

For further details please contact: 
Johan Hähnel 
Investor Relations Manager
Telephone: +46 70 605 63 34
Email:  investor@cavotec.com

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Bavarian Nordic modtager vaccineordre fra europæisk land efter bekræftede tilfælde af abekopper19.5.2022 11:46:42 CEST | pressemeddelelse

KØBENHAVN, Danmark, 19. maj 2022 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at selskabet har indgået en kontrakt med et unavngivet europæisk land vedrørende levering af koppevaccinen IMVANEX® i forbindelse med nye tilfælde af abekopper, der er identificeret i løbet af maj 2022. Det første europæiske tilfælde blev bekræftet den 7. maj 2022 hos en person, der vendte hjem fra en rejse til Nigeria, hvor abekopper er naturligt forekommende. Efterfølgende er der bekræftet mere end 20 tilfælde i England, Portugal og Spanien, og flere formodede tilfælde er ved at blive undersøgt. De fleste infektioner lader til at være sket lokalt i de tre lande. I USA er der bekræftet et enkelt tilfælde hos en rejsende fra Canada, hvor der endnu ikke foreligger bekræftede tilfælde, men adskillige formodede tilfælde er ved at blive undersøgt. Bavarian Nordics koppevaccine er godkendt i USA under navnet JYNNEOS® og i Canada under navnet IMVAMUNE®. I begge lande er godkendelsen udvidet til at omfatte abek

Bavarian Nordic Secures Vaccine Order from European Country After Confirmed Monkeypox Cases19.5.2022 11:46:42 CEST | Press release

COPENHAGEN, Denmark, May 19, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Company has secured a contract with an undisclosed European country to supply its IMVANEX® smallpox vaccine in response to new cases of monkeypox evolving during May 2022. The first European case was confirmed on May 7, 2022, in an individual who returned from a travel to Nigeria, where monkeypox is endemic. Subsequently, more than 20 cases have been confirmed across England, Portugal and Spain with additional suspected cases currently being investigated. Evidence points to that most of the infections have been acquired locally in these countries. In the US, a single case has been confirmed in a traveler from Canada, where no cases are yet confirmed, but several remain under investigation. Bavarian Nordic’s smallpox vaccine is approved in the U.S. as JYNNEOS® and in Canada as IMVAMUNE®, both places with the approval extended to cover the monkeypox indication. The vaccine is approved in Europe a

XPENG Oslo Experience Store Now Open With XPENG G3i and XPENG P5 Available for Local Test Drives19.5.2022 11:00:00 CEST | Press release

XPENG opens its first Brand Experience Store in the Bjørvika area of downtown Oslo on May 19, 2022.The launch of the fully electric XPENG P5 and XPENG G3i makes Norway the first European country to boast the full range of XPENG EVs. Local test drives are now available to customers.XPENG, in June this year, will be participating in the 35th International Electric Vehicle Symposium (EVS35) 2022, the world’s largest international EV event live from Oslo. OSLO, Norway, May 19, 2022 (GLOBE NEWSWIRE) -- XPENG, a leading electric vehicle manufacturer, is taking the next step in its European expansion by opening its first Norwegian Brand Experience Store in the Bjørvika area of Oslo on May 19. This coincides with the official launch of the brand's two latest models, XPENG G3i and XPENG P5. Establishing a Local Presence XPENG is one of the early adopters of a disruptive retail model in the European market, combining direct, in-store sales with wider agency collaboration. In the Oslo Brand Exper

IBFD launches the 2021 Yearbook on Taxpayers’ Rights19.5.2022 10:00:00 CEST | Press release

Today, IBFD launches the 2021 Yearbook on the Protection of Taxpayers’ Rights (OPTR). The book is a compilation of up-to-date information on the effective protection of taxpayers’ rights. AMSTERDAM, May 19, 2022 (GLOBE NEWSWIRE) -- Prof. Dr Pasquale Pistone and Prof. Dr Philip Baker, Directors of IBFD’s OPTR, will present the Yearbook at the 7th International Conference on Taxpayer Rights, hosted by the Center for Taxpayer Rights, explaining some of the main events and trends that arose last year in the protection of taxpayers’ rights around the world. Click here to watch the video. The OPTR reports on the protection of taxpayers’ fundamental rights around the world. The precise and technical information of the OPTR contains reference to taxpayer bills, conventions and statutes, including their judicial and administrative interpretation, which explore how states apply this protection in practice. The OPTR serves as a unique legal basis for developing further research on the legal remed

Centrient Pharmaceuticals announces its achievement of a significant milestone in the clean production of antibiotics19.5.2022 10:00:00 CEST | Press release

Being the first company to publicly announce 100% PNEC compliance for its entire oral antibiotics product range Rijswijk, The Netherlands, May 19, 2022 (GLOBE NEWSWIRE) -- Summary Centrient Pharmaceuticals reached a significant milestone in the clean production of its antibiotics, with the lowest environmental impact and minimizing the potential contribution to antimicrobial resistanceThe company is the first to publicly announce that Its entire supply chain of oral antibiotics – including its own and supplier manufacturing sites - is fully compliant with the stringent Predicted No Effect Concentration (PNEC) discharge targets set by the AMR Industry AllianceThis achievement demonstrates Centrient Pharmaceuticals’ commitment and leadership in the responsible production of antibiotics. Centrient Pharmaceuticals announces 100% compliance with the stringent Predicted No Effect Concentration (PNEC) discharge targets set by the AMR Industry Alliance for clean manufacturing of its full oral